

CLAIMS

1. Use of a composition in the manufacture of a medicament for treating cancer wherein the composition comprises an anti-CD20 antibody and/or an antibody that binds to CD47 or an antigen-binding fragment thereof comprising a variable heavy chain (VH) CDR1 comprising SEQ ID NO: 50, a VH CDR2 comprising SEQ ID NO: 72, a VH CDR3 sequence comprising SEQ ID NO: 52, a variable light chain (VL) CDR1 comprising SEQ ID NO: 53, a VL CDR2 comprising SEQ ID NO: 71, and a VL CDR3 comprising SEQ ID NO: 55.
2. The use according to claim 1 wherein the anti-CD20 antibody is rituximab.
3. The use according to claim 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising a sequence selected from the group consisting of SEQ ID NOs: 6 and 11.
4. The use according to any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof comprises a VL comprising a sequence selected from the group consisting of SEQ ID NOs: 42 and 46.
5. The use according to any one of claims 1 to 4, wherein the antibody or antigen-binding fragment thereof is an IgG isotype selected from the group consisting of IgG1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype.
6. The use according to any one of claims 1 to 4, wherein the antibody or antigen-binding fragment thereof is an IgG isotype selected from IgG4P and IgG4PE.
7. The use according to any one of claims 1 to 6, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
8. The use according to any one of claims 1 to 7, wherein the composition is to be administered serially, sequentially, concurrently or concomitantly.

9. The use according to any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject at a dose of 0.3, 1, 2, 4, 8, 15, or 20 mg/kg.
- 5 10. The use according to any one of claims 1 to 9, wherein the anti-CD20 antibody is to be administered to the subject at a dose of 300, 325, 350, 375, 400, 425, 450, or 500 mg/m².
- 10 11. The use according to any one of claims 1 to 10, wherein the composition further comprises another anti-cancer agent.
12. The use according to any one of claims 1 to 11, wherein the cancer is a hematological cancer.
- 15 13. The use according to claim 12, wherein the hematological cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia (AML).
14. The use according to any one of claims 1 to 13, wherein the composition does not comprise a proteasome inhibitor.
- 20 15. The use according to claim 14, wherein the proteasome inhibitor is bortezomib.
16. The use according to any one of claims 1 to 15, wherein the composition does not comprise methotrexate.